GHRP-2

Mechanism

GHS-R1a agonist that can raise GH with cortisol/prolactin spillover.

Reported effects

What sources associate with this compound. Reported categories, not outcomes we have graded — each would need its own citation and rung.

• GH pulse amplification
• Appetite stimulation
• Legacy comparator

Reconstitution

mass ÷ diluent = concentration; dose ÷ concentration = volume; volume × the syringe factor = units on the barrel (100 for U-100, 40 for U-40). Run your own numbers.

Reported adverse effects

• Increased appetite

  Commononset: Post-injectionreported reversible

• Transient cortisol and prolactin elevation at higher doses

  Dose-dependentonset: Post-injectionreported reversible

Literature on file 5

• human case series
  Pituitary dysfunction in trans-sellar encephalocele: a two-case report and a literature review. graded on: a case report or series — “case report”
• human observational
  Endocrine disorders in pediatric medulloblastoma survivors treated with X-ray or proton beam therapy: a single-institution retrospective study. graded on: an observational human design — “retrospective”

Not graded

3 citations whose study design could not be read from the title. Left ungraded rather than guessed at.

• not graded
  The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.
• not graded
  Growth Hormone-Releasing Peptides: Investigation of Their Secondary Structure, Thermal Stability, and Model Membrane Interactions.
• not graded
  Benchmark for Setting ACTH Cell Dosage in Clinical Regenerative Medicine for Post-Operative Hypopituitarism.

Identity

PubChem CID 6918245 computed 3D conformer

Skeletal formulathe canonical depiction

Drawn by PubChem from CID 6918245, the identifier on this record.

Molecular weight

818.0

Molecular formula

C45H55N9O6

CAS number

158861-67-7

PubChem CID

6918245

InChI key

HRNLPPBUBKMZMT-RDRUQFPZSA-N

Sequence

AXAWFK

SMILES

C[C@H](C(=O)N[C@H](CC1=CC2=CC=CC=C2C=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@H](CC5=CC=CC=C5)C(=O)N[C@@H](CCCCN)C(=O)N)N

InChI

InChI=1S/C45H55N9O6/c1-27(47)41(56)52-38(24-30-19-20-31-14-6-7-15-32(31)22-30)43(58)50-28(2)42(57)53-39(25-33-26-49-35-17-9-8-16-34(33)35)45(60)54-37(23-29-12-4-3-5-13-29)44(59)51-36(40(48)55)18-10-11-21-46/h3-9,12-17,19-20,22,26-28,36-39,49H,10-11,18,21,23-25,46-47H2,1-2H3,(H2,48,55)(H,50,58)(H,51,59)(H,52,56)(H,53,57)(H,54,60)/t27-,28+,36+,37-,38-,39+/m1/s1

Classified as

Ghrelin Receptor Agonismmechanism

This is the mechanism behind the compounds usually filed as secretagogues, and it explains why appetite effects appear in the same records as growth hormone effects rather than as an unrelated aside.

Subcutaneousroute

This is the route the reconstitution arithmetic assumes. Mass divided by diluent volume gives concentration, dose divided by concentration gives volume, and volume in mL multiplied by 100 gives units on a U-100 barrel: 5 mg in 2 mL is 2.5 mg/mL, and 0.25 mg comes out at 0.1 mL, which is 10 units.

Intranasalroute

A nasal device delivers a fixed volume per spray, so concentration rather than syringe volume sets the amount per spray, and a mass figure on a record is not usable until you know how many actuations it was divided across.

Intravenousroute

A large share of the pharmacokinetic numbers attached to peptide records, half-life in particular, come from intravenous studies and often from animals. Those numbers describe an intravenous curve and do not transfer unchanged to a depot under the skin.

Also called

• GHRP-2
• Pralmorelin
• growth hormone-releasing peptide-2
• pralmorelinum

Share this record